Abstract 446P
Background
Patients with cancer often develop cachexia. There has been no clearly effective treatment for this condition. However, anamorelin is approved for the treatment of cancer cachexia associated with advanced non-small cell lung cancer.
Methods
We conducted a retrospective analysis of treatment efficacy, adverse events and background factors in non-small cell lung cancer patients treated with anamorelin for cancer cachexia at our hospital from 1 April 2021 to 30 April 2023. Anamorelin effective cases were defined as those with improved performance status (PS) or appetite.
Results
A total of 68 patients were treated with anamorelin during the study period. The median age was 76.5 (59-92) years and the male patients were predominantly. Comorbidities included COPD (29.4%), interstitial pneumonia (22.1%). The clinical stage of lung cancer was stage 4 in 75.7% of patients. The median duration of anamorelin treatment was 36 (1-714) days. Anamorelin improved anorexia in 32 patients and PS in 21 patients. According to the definition of our study, there were 34 patients with anamorelin response and 34 patients without response. The patients with anamorelin response had a significantly longer duration of treatment (P<0.01) and significantly lower C-reactive protein (CRP) before treatment (P=0.04) compared to the patients without anamorelin response. The most common adverse events were nausea (14.7%), appetite loss (13.2%), hyperglycemia (11.8%) and liver damage (10.3%), respectively. Three patients experienced G3≤ adverse events. Fourteen (20.6%) patients discontinued anamorelin due to adverse events. The frequency of adverse events did not differ between the two groups.
Conclusions
Anamorelin improved appetite or PS in half of the patients in this retrospective study. In contrast, 14 (20.6 %) patients discontinued treatment due to adverse events. Anamorelin may be more effective in patients with lower CRP levels prior to treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
T. Ito.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract